复方纳米雄黄中砷在大鼠体内的药动学  

Pharmacokinetics of arsenic in the compound nano-realgar in rats

作　　者：王晓波[1] 袭荣刚[1] 杨小丽[1] 杨晓波[1] 

机构地区：[1]中国人民解放军第210医院,大连116021

出　　处：《中国新药杂志》2007年第21期1758-1761,共4页Chinese Journal of New Drugs

基　　金：自然科学基金资助课题(30572369)

摘　　要：目的:研究复方纳米雄黄中砷在大鼠体内的药动学行为。方法:用氢化物发生-双道原子荧光光谱法测定血清中砷元素的浓度,并计算药动学参数。结果:低、中、高(35,70,140 mg·kg^(-1))三剂量组主要药动学参数分别为t_(1/2)Ka:0.34,0.30,0.29 h;t_(1/2)Ke:19.0,21.6,22.1 h;CL/F:7.1,6.5,6.0 mL·kg^(-1)·h^(-1);V_d/F:188.6,200.1,191.0 mL·kg^(-1);C_(max):180.9,334.4,693.1 ng·mL^(-1);AUC:5069,10650,23393 ng·mL^(-1)·h。除C_(max)和AUC外,其他药动学参数在3种剂量组间比较和雌雄性别之间比较,差异均无统计学意义(P>0.05),而C_(max)和AUC则与剂量呈正比。结论:复方纳米雄黄中砷在大鼠体内的药动学行为符合开放性血管外给药一室模型一级速率过程。Objective： To study the pharmacokinetics of arsenic in the compound nano-realgar containing arsenic in rats. Methods： The concentration of arsenic in the samples was determined by hydride generation-atomic fluorescence spectroscopy （HG-AFS）. The pharmacokinetic parameters were calculated using 3P97 software. Results： The main pharmacokinetic parameters of arsenic after administration of 3 doses of compound nano-realgar （35, 70 and 140 mg·kg^-1） were as follows： t1/2Ka （0.34, 0. 30 and 0.29 h, respectively）; t1/2Ke （19.0, 21.6 and 22.1 h）; CL/F （ 7.1, 6.5 and 6.0 mL·kg·^-1·h^-1）; Vd/F （188.6, 200. 1 and 191.0 mL·kg^-1） ; Cmax（180.9, 334.4 and 693.1 ng·mL^-1） ; AUC （5 069, 10 650 and 23 393 ng·mL^-1·h）. Except AUC and C no significant differences were observed in the parameters among the 3 doses and both sexes. Conclusion：The pharmacokinetics of arsenic in the compound nano-realgar in rats is fit to a one-compartment model.

关 键 词：砷 纳米雄黄 复方黄黛片 药动学 

分 类 号：R285.5[医药卫生—中药学] R945[医药卫生—中医学]